Back Back
Cell No. : Cell Name
RCB1640 : DAUDI  update : 2024/01/17
CommentBurkitt's lymphoma. Sensitive to lymphokine-activated killer cells but resistant to natural killer cells. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85011437 prior to order.
Comment from the depositor
Terms and conditions1) There is no restriction regarding use for basic researches. However, since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECA85011437 prior to order. 2) In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor ECACC
Year of deposit 2000
Animal _human < Mammals
Genus Homo
Species sapiens
Race Negloid
Gender Male
Age at sampling 16 years
Tissue blood
Disease name Burkitt's lymphoma
Classification cancer
History overseas, ECACC -> RIKEN Cell Bank
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_0008
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Culture medium RPMI1640 + 10% FBS
Culture method
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 10 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) LT 400
Virus (HTLV-1) (-)
Virus (EBV) (+)
Isozyme LD, NP
Chromosome mode 46-47(50) : 46(10),48(40)
STR(human) OK
Reference information Reference 6
User's Publication 12

To topTop
5042  Haruta Y, Seon BK.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.  Proc Natl Acad Sci U S A  1986  83(20):7898-902  PubMed ID: 3464004   DOI: 10.1073/pnas.83.20.7898
2417  Nilsson K, Giovanella, B C, Stehlin, J S, Klein G  Tumorigenicity of human hematopoietic cell lines in athymic nude mice.  Int J Cancer  1977  19:337-44  PubMed ID: 14896   DOI: 10.1002/ijc.2910190309
1141  Ralph P, Moore, M A, Nilsson K  Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines.  J Exp Med  1976  143:1528-33  PubMed ID: 1083890   DOI: 10.1084/jem.143.6.1528
4975  Neumann H, Klein E, Hauck-Granoth R, Yachnin S, Ben-Bassat H.  Comparative study of alkaline phosphatase activity in lymphocytes, mitogen-induced blasts, lymphoblastoid cell lines, acute myeloid leukemia, and chronic lymphatic leukemia cells.  Proc Natl Acad Sci U S A  1976  73(5):1432-6  PubMed ID: 1064015   DOI: 10.1073/pnas.73.5.1432
971  Klein E, Klein G, Nadkarni, J S, Nadkarni, J J, Wigzell H, Clifford P  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.  Cancer Res  1968  28:1300-10  PubMed ID: 4174339  
2416  Klein E, Klein G, Nadkarni, J S, Nadkarni, J J, Wigzell H, Clifford P  Surgace IgM specificity on cells derived from a Burkitt's lymphoma.  Lancet  1967  2:1068-70  PubMed ID: 4168541   DOI: 10.1016/s0140-6736(67)90340-6

To topTop
User's Publication
16945  Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, Tamaru JI, Mukasa A, Matsuoka M, Komohara Y.  Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy  Cancer Sci  2022  113(6):2129-2143  PubMed ID: 35343027   DOI: 10.1111/cas.15349
13229  Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, Soejima K, Nakajima J.  Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.  J Immunother Cancer  2020    PubMed ID: 32948652   DOI: 10.1136/jitc-2020-001185
5030  Tsukamoto M, Imai K, Ishimoto T, Komohara Y, Yamashita YI, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Miyata T, Arima K, Okabe H, Baba Y, Chikamoto A, Ishiko T, Hirota M, Baba H.  PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.  Cancer Sci  2019  110(1):310-320  PubMed ID: 30426611   DOI: 10.1111/cas.13874
10069  Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M.  PD-L1 expression in papillary renal cell carcinoma.  BMC Urol  2017  17:8  PubMed ID: 28086852   DOI: 10.1186/s12894-016-0195-x
10269  Komohara Y, Ma C, Yano H, Pan C, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Okuno Y, Nosaka K, Shimosaki S, Morishita K, Matsuoka M, Wakayama T, Takeya M.  Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages  J Clin Exp Hematop  2017  57:15-20  PubMed ID: 28420814   DOI: 10.3960/jslrt.17003
13994  Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y.  An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma  Cancer Sci  2016  107(11):1696-1704  PubMed ID: 27564404   DOI: 10.1111/cas.13065
14309  Ninomiya S, Kawano M, Abe T, Ishikawa T, Takahashi M, Tamura M, Takahashi Y, Nashimoto M.  Potential small guide RNAs for tRNase ZL from human plasma, peripheral blood mononuclear cells, and cultured cell lines  PLoS One  2015  10(3):e0118631  PubMed ID: 25730316   DOI: 10.1371/journal.pone.0118631
13727  Goto H, Matsuda K, Srikoon P, Kariya R, Hattori S, Taura M, Katano H, Okada S.  Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma  Cancer Lett  2013  331(2):174-82  PubMed ID: 23321500   DOI: 10.1016/j.canlet.2012.12.021
15339  Bai B, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Takeya M, Komohara Y.  Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: the in vitro study  J Clin Exp Hematop  2013  53(2):127-33  PubMed ID: 23995109   DOI: 10.3960/jslrt.53.127
16574  Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K.  Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain  Cytotherapy  2013  15(4):481-91  PubMed ID: 23391461   DOI: 10.1016/j.jcyt.2012.12.004
2320  Kim C, Matsumura M, Saijo K, Ohno T.  In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.  Cancer Immunol Immunother.  1998  47(2):90-6  PubMed ID: 9769117   DOI: 10.1007/s002620050508
2318  Liu SQ, Kawai K, Shiraiwa H, Hayashi H, Akaza H, Hashizaki K, Shiba R, Saijo K, Ohno T.  High rate of induction of human autologous cytotoxic T lymphocytes against renal carcinoma cells cultured with an interleukin cocktail.  Jpn J Cancer Res  1998  89(11):1195-201  PubMed ID: 9914789   DOI: 10.1111/j.1349-7006.1998.tb00515.x

Back Back Return Top Page